Welcome to Lilly Scientific Information Page for CTAD 2025
Clinical Trials on Alzheimer's Disease
San Diego, California
Quicklinks
See how Lilly supports external requests for provision of study drug and/or financial support.
To stay informed on the latest science and innovation, please be sure to follow us on Twitter/X
To receive the latest science and innovation, please be sure to follow us on LinkedIn.
Disclosures
MONDAY
- Disease State: Alzheimer's Disease
- Presented by: Hong Wang
- Molecule(s): Donanemab
The Effect of Corticosteroid Pre-Treatment with Modified Titration of Donanemab on Amyloid Reduction and Safety: TRAILBLAZER-ALZ 6 Addendum Design
Trial(s) Overview:
TRAILBLAZER-ALZ 6
MONDAY
- Disease State: Alzheimer's Disease
- Presented by: Matthew Hufford
- Molecule(s): Remternetug
Feasibility of Participants with Symptomatic Alzheimer's Disease to Self-Administer Remternetug Subcutaneously: Results from the TRAILRUNNER-ALZ 1 Phase 3 Trial
Trial(s) Overview:
TRAILRUNNER-ALZ 1
MONDAY
- Disease State: Alzheimer's Disease
- Presented by: Paul Ardayfio
- Molecule(s): Donanemab
Baseline use of Antihypertensive Medication is Associated with Reduced Frequency of Amyloid-Related Imaging Abnormalities-Edema with Donanemab: Results from the TRAILBLAZER Randomized Clinical Trials
Trial(s) Overview:
TRAILBLAZER-ALZ 1
TRAILBLAZER-ALZ 2
MONDAY
- Disease State: Alzheimer's Disease
- Presented by: Leanne Munsie
- Molecule(s): Ceperognastat
Clinical, Safety, and Biomarker Outcomes From a Posttreatment Observational Extension of the Phase 2 PROSPECT-ALZ Study of Ceperognastat in Early Symptomatic Alzheimer’s Disease
Trial(s) Overview:
PROSPECT-ALZ
WEDNESDAY
- Disease State: Alzheimer's Disease
- Presented by: Rose Beck
- Molecule(s): Lilly SPX P-tau217 Assay
P-tau217 Testing Impact on Patient Management in a Racially/Ethnically Diverse Population: Six-Month Follow up in a Randomized Clinical Utility Study
Trial(s) Overview:
Not Applicable
WEDNESDAY
- Disease State: Alzheimer's Disease
- Presented by: Roy Yaari
- Molecule(s): Solanezumab
Prognostic Models for Development of Elevated Plasma P-tau217 in Preclinical Alzheimer’s Disease: Insights from A4/LEARN
Trial(s) Overview:
A4/LEARN
WEDNESDAY
- Disease State: Alzheimer's Disease
- Presented by: Ron DeMattos
- Molecule(s): Not Applicable
Next Generation Anti-Amyloid Therapies ...Shuttling Past the ARIA Risk
Trial(s) Overview:
Not Applicable
WEDNESDAY
- Disease State: Alzheimer's Disease
- Presented by: Diana Svaldi
- Molecule(s): Donanemab
Head-to-Head Comparison of SWI and T2*-Weighted Gradient Echo MRI Sequences to Detect ARIA-H in the TRAILBLAZER-ALZ 6 Trial of Donanemab
Trial(s) Overview:
TRAILBLAZER-ALZ 6
WEDNESDAY
- Disease State: Alzheimer's Disease
- Presented by: Jennifer Zimmer
- Molecule(s): Donanemab
Donanemab in Early Symptomatic Alzheimer's Disease: Additional Insights from the TRAILBLAZER‐ALZ 2 Long-Term Extension
Trial(s) Overview:
TRAILBLAZER-ALZ 2
THURSDAY
- Disease State: Alzheimer's Disease
- Presented by: Diego Novick
- Molecule(s): Not Applicable
Cognitive Trajectories in Alzheimer's Disease: Findings from the Multinational CICERO-AD Chart Review Study
Trial(s) Overview:
CICERO-AD (Not a clinical trial)
THURSDAY
- Disease State: Alzheimer's Disease
- Presented by: Eric Klein
- Molecule(s): Not Applicable
Impact of Telemedicine on Time and Process Measures Associated with Detection and Diagnosis of Alzheimer's Disease
Trial(s) Overview:
Not Applicable
THURSDAY
- Disease State: Alzheimer's Disease
- Presented by: Nalin Payakachat
- Molecule(s): Solanezumab
Development of Prognostic Models for Five-Year Risk of Clinical Progression from Preclinical Alzheimer’s Disease (Stage 1 and 2) to Cognitive Impairment: Findings from the A4 Study
Trial(s) Overview:
A4/LEARN
THURSDAY
- Disease State: Alzheimer's Disease
- Presented by: Oralee Varnado
- Molecule(s): Not Applicable
Neurologists’ Perceptions and Experiences with Amyloid-Targeting Therapies in Alzheimer’s Disease in the United States: Baseline Data
Trial(s) Overview:
Not Applicable
THURSDAY
- Disease State: Alzheimer's Disease
- Presented by: Karen Holdridge
- Molecule(s): Donanemab
Recruitment and Screening in TRAILBLAZER-ALZ 3: A Decentralized Study of Donanemab in Preclinical Alzheimer’s Disease
Trial(s) Overview:
TRAILBLAZER-ALZ 3
To receive the latest science and innovation from LillyMedical, be sure to follow us via our Twitter handle @LillyMedical. See our community guidelines.
Contact Us
Call us
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)